Rune Nørgaard Rasmussen
Research Subjects
Rune Nørgaard Rasmussen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Uhd Nielsen
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55 DK-5230, Odense M, Denmark
4 shared publications René Holm
Drug Product Development, Janssens Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium
4 shared publicationsCandela Lagunas
Drug Transporters in ADME, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen, Denmark
2 shared publications- Kenneth Vielsted Christensen
H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark
2 shared publications Benafsha Noori
Drug Transporters in ADME, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen , Universitetsparken 2, DK-2100 Copenhagen, Denmark
1 shared publication- Carolina Säll
Development ADME Novo Nordisk A/S Måløv Denmark
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70732
Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.
- 23 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70732
Open AccessReal‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.
- 25 July 2016
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (9) , 3119-3129
A Transporter of Ibuprofen is Upregulated in MDCK I Cells under Hyperosmotic Culture Conditions
Ibuprofen is a widely used drug. It has been identified as an inhibitor of several transporters, but it is not clear if ibuprofen is a substrate of any transporter itself. In the present work, we have characterized a transporter of ibuprofen, which is upregulated by hyperosmotic culture conditions in Madin–Darby canine kidney I (MDCK I) renal cells. [3H]-Ibuprofen uptake rate was measured in MDCK I cell cultured under normal (300 mOsm) and hyperosmotic (500 mOsm) conditions. Hyperosmotic conditions were obtained by supplementing urea, NaCl, mannitol, or raffinose to culture medium. The effect of increased osmolarity was investigated for different incubation times. [3H]-Ibuprofen uptake in MDCK I cells was upregulated by hyperosmotic culture condition, and was saturable with a Km value of 0.37 ± 0.08 μM and a Vmax of 233.1 ± 17.2 pmol· cm–2· min–1. Racemic [3H]-ibuprofen uptake could be inhibited by (R)-(−)- and (S)-(+)-ibuprofen with IC50 values of 19 μM (Log IC50 1.39 ± 0.34) and 0.47 μM (Log IC50 −0.36 ± 0.41), respectively. Furthermore, the [3H]-ibuprofen uptake rate was increased by decreased extracellular pH but not dependent on Na+ or Cl– ions. The mRNA of Mct1, -2, -4, and -6 as well as Oat1 and -3 were not upregulated by hyperosmolarity. Our findings present strong evidence for the presence of a yet unknown ibuprofen transporter in MDCK I cells. The transporter was upregulated under hyperosmotic culture conditions, and the present study is therefore a starting point for identification of the molecular correlate and potential impact on ibuprofen disposition.
- 25 July 2016
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (9) , 3119-3129
A Transporter of Ibuprofen is Upregulated in MDCK I Cells under Hyperosmotic Culture Conditions
Ibuprofen is a widely used drug. It has been identified as an inhibitor of several transporters, but it is not clear if ibuprofen is a substrate of any transporter itself. In the present work, we have characterized a transporter of ibuprofen, which is upregulated by hyperosmotic culture conditions in Madin–Darby canine kidney I (MDCK I) renal cells. [3H]-Ibuprofen uptake rate was measured in MDCK I cell cultured under normal (300 mOsm) and hyperosmotic (500 mOsm) conditions. Hyperosmotic conditions were obtained by supplementing urea, NaCl, mannitol, or raffinose to culture medium. The effect of increased osmolarity was investigated for different incubation times. [3H]-Ibuprofen uptake in MDCK I cells was upregulated by hyperosmotic culture condition, and was saturable with a Km value of 0.37 ± 0.08 μM and a Vmax of 233.1 ± 17.2 pmol· cm–2· min–1. Racemic [3H]-ibuprofen uptake could be inhibited by (R)-(−)- and (S)-(+)-ibuprofen with IC50 values of 19 μM (Log IC50 1.39 ± 0.34) and 0.47 μM (Log IC50 −0.36 ± 0.41), respectively. Furthermore, the [3H]-ibuprofen uptake rate was increased by decreased extracellular pH but not dependent on Na+ or Cl– ions. The mRNA of Mct1, -2, -4, and -6 as well as Oat1 and -3 were not upregulated by hyperosmolarity. Our findings present strong evidence for the presence of a yet unknown ibuprofen transporter in MDCK I cells. The transporter was upregulated under hyperosmotic culture conditions, and the present study is therefore a starting point for identification of the molecular correlate and potential impact on ibuprofen disposition.
- 21 July 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (10) , 1916-1924
Ibuprofen transport in renal cell cultures: characterization of an ibuprofen transporter upregulated by hyperosmolarity
In the present study, we have investigated ibuprofen transport in renal cell cultures with the aim of characterizing a recently proposed ibuprofen transporter. We here show that hyperosmolarity upregulates an ibuprofen transporter in dog renal MDCK I cells via increased mRNA and protein synthesis, while the transporter was not upregulated by hyperosmolarity in porcine and rat renal cell lines. The transport of ibuprofen in MDCK I cells was inhibited by ibuprofen metabolites such as 1- and 3-hydroxyibuprofen, and to a lesser extent by 2-hydroxyibuprofen. Other non-steroidal anti-inflammatory drugs such as naproxen, ketoprofen, flurbiprofen, diclofenac, and piroxicam also inhibited ibuprofen transport while no effect was observed from acetylsalicylic acid. The transporter was functionally detected in both the apical and basolateral membranes of MDCK 1 cells, and may control intracellular concentrations of ibuprofen.
- 21 July 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (10) , 1916-1924
Ibuprofen transport in renal cell cultures: characterization of an ibuprofen transporter upregulated by hyperosmolarity
In the present study, we have investigated ibuprofen transport in renal cell cultures with the aim of characterizing a recently proposed ibuprofen transporter. We here show that hyperosmolarity upregulates an ibuprofen transporter in dog renal MDCK I cells via increased mRNA and protein synthesis, while the transporter was not upregulated by hyperosmolarity in porcine and rat renal cell lines. The transport of ibuprofen in MDCK I cells was inhibited by ibuprofen metabolites such as 1- and 3-hydroxyibuprofen, and to a lesser extent by 2-hydroxyibuprofen. Other non-steroidal anti-inflammatory drugs such as naproxen, ketoprofen, flurbiprofen, diclofenac, and piroxicam also inhibited ibuprofen transport while no effect was observed from acetylsalicylic acid. The transporter was functionally detected in both the apical and basolateral membranes of MDCK 1 cells, and may control intracellular concentrations of ibuprofen.
- 1 January 2016
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 82, 138-146
Interaction of GABA-mimetics with the taurine transporter (TauT, Slc6a6) in hyperosmotic treated Caco-2, LLC-PK1 and rat renal SKPT cells
- 1 January 2016
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 82, 138-146
Interaction of GABA-mimetics with the taurine transporter (TauT, Slc6a6) in hyperosmotic treated Caco-2, LLC-PK1 and rat renal SKPT cells
- 1 December 2014
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (12) , 4021-4029
A Prodrug Approach Involving In Situ Depot Formation to Achieve Localized and Sustained Action of Diclofenac After Joint Injection
- 1 December 2014
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (12) , 4021-4029
A Prodrug Approach Involving In Situ Depot Formation to Achieve Localized and Sustained Action of Diclofenac After Joint Injection